1. Home
  2. ICL vs IOVA Comparison

ICL vs IOVA Comparison

Compare ICL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICL Group Ltd.

ICL

ICL Group Ltd.

N/A

Current Price

$4.14

Market Cap

7.3B

Sector

Industrials

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$7.41

Market Cap

6.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ICL
IOVA
Founded
1968
2007
Country
Israel
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
6.7B
IPO Year
2001
2008

Fundamental Metrics

Financial Performance
Metric
ICL
IOVA
Price
$4.14
$7.41
Analyst Decision
Hold
Buy
Analyst Count
4
9
Target Price
$5.74
★ $14.50
AVG Volume (30 Days)
2.1M
★ 12.8M
Earning Date
11-10-2026
11-05-2026
Dividend Yield
★ 4.72%
N/A
EPS Growth
N/A
★ 14.84
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.83
$58.86
Revenue Next Year
$3.48
$41.86
P/E Ratio
$31.41
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.10
$2.08
52 Week High
$6.97
$15.37

Technical Indicators

Market Signals
Indicator
ICL
IOVA
Relative Strength Index (RSI) 25.23 31.10
Support Level N/A $3.57
Resistance Level $5.79 $9.36
Average True Range (ATR) 0.12 0.57
MACD -0.03 -0.13
Stochastic Oscillator 4.58 4.34

Price Performance

Historical Comparison
ICL
IOVA

About ICL ICL Group Ltd.

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates revenue from Brazil, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: